Practical Support That Continues Every Day

In addition to offering financial support and options to help pay for ENBREL, ENBREL Support™ provides tools, resources, and practical support to your patients—all at no cost to them.

Resources for Starting ENBREL

ENBREL Support™ offers tools to help patients get started with ENBREL treatment, like StartingENBREL.com, an online guide to help patients through their first few weeks.

The ENBREL Starter Kit is also full of information for new patients and includes a progress journal, convenient travel pack, and helpful magnetic calendar.

Online Videos and Demos

ENBREL Support™ Videos

Available on the patient site, these videos outline all the support available to patients while they are taking ENBREL.

RAconversations Video Series

Empower your patients with RAconversations, a video series designed to foster communication about RA between patients and their doctors.

Step-by-step Injection Demos

After being trained on how to properly inject by their doctor or an appropriate health care professional, patients can view these demos online that walk them through the injection process, one step at a time.

Services to Keep Patients on Track

Medication Reminders

We offer friendly opt-in injection and refill reminders, available via phone or e-mail, that help patients keep ENBREL on their schedules.

ENBREL Sharps Mail-Back Program

This is a simple, convenient, and eco-friendly solution for ordering and returning sharps containers provided at no cost to patients.

Live Support from Nurses and Insurance Specialists

Whether patients call 1-888-4ENBREL or use our convenient Schedule-a-Call Tool, they can connect to a registered nurse, 7 days a week, 8 AM to 11 PM (ET), who can help to answer questions about injections, storing ENBREL, traveling with the medication, side effects, and more.

And when patients have questions about insurance, our specialists are available Monday through Friday, 8 AM to 8 PM, to give them personalized answers about their coverage. Or they can visit CheckENBRELInsurance.com, 24 hours a day.

 
Important Safety Considerations

More than 170,000 people have used the ENBREL Support™ card to help pay for ENBREL

Learn about our program

The experience of ENBREL

Evaluated in clinical studies over the past 19 years*

See our history of "1sts"
*Initial clinical research in RA patients began in 1993. Approved to treat moderate to severe RA in 1998.
 
 
Close
You are leaving Enbrel.com/RheumPro
Please know that Amgen and Pfizer do not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320 and Pfizer Inc
Close
E-mail this page to a colleague
Please correct the fields marked in red
Send
This content is for US health care professionals only. Amgen and Pfizer will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.
Close

Send another e-mail
Return to enbrel.com/RheumPro

Close
Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Pfizer website and the Amgen website to find information about our offices around the globe.
Close
Phil Mickelson: A patient's perspective
Close
Disease activity vs. structural progression in RA